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Abstract – 
Cell-free protein synthesis (CFPS) is an in vitro protein synthesis system that provides a uniquely 
adaptable platform for protein production. In recent years, lyophilization of CFPS have expanded the 
capabilities of this system by improving reagent stability outside of cold-chain storage. This project sought 
to utilize lyophilized CFPS reagents to develop a convenient, shelf-stable, on-demand therapeutic protein 
production platform. The therapeutic protein production potential of this novel platform was demonstrated 
by the successful expression of an FDA approved therapeutic protein.  With the advancement of shelf-
stable, on-demand protein therapeutic production platforms comes the potential to provide point-of-care 
medical treatment for space-flight crews during long duration missions.  
 
Introduction 
As the dream of long-term space exploration 
becomes a reality, so do the unique health risks 
associated with space flight. Missions requiring 
long-duration habitation beyond low-earth orbit 
pose significant challenges to the health and 
well-being of the crew. Successful medical 
interventions, as well as biomedical 
countermeasures to prevent or mitigate high-risk 
conditions, are contingent on the therapeutics 
available to the crew. Some of the most 
beneficial options for medical care are protein 
therapeutics, as they provide particularly 
effective treatments for cancer, genetic diseases, 
neurological disorders, and radiation syndromes. 
However, the availability of protein therapeutics 
is limited by their low stability under high-levels 
of radiation and long term storage [1].  
This project sought to overcome the challenges 
of protein therapeutic availability during long-
term space flight by engineering a lyophilized 
cell-free protein synthesis (CFPS) system 
capable of producing protein therapeutics on 
demand and thus provide life-saving treatments 
to space flight crews.   
Relevance to NASA Aims 
This work focuses on supporting Strategic Goal 
2 of NASA’s 2018 Strategic Plan which is to 
“Extend Human Presence Deeper into Space and 
to the Moon for Sustainable Long-term 
Exploration and Utilization” [2]. In particular, 
this proposal addresses the specific challenges 
identified in the NASA Technology Roadmaps: 
pharmaceutical stability under space flight 
conditions (TA 6.3.2), effective treatment 
options for high-risk medical conditions for long-
duration health (TA 6.5.2) [3]. These challenges 
can be addressed through on-demand production 
of protein therapeutics during long-term space 
flight.  
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Protein therapeutic availability on board 
spacecraft can improve treatment options and 
countermeasures during interplanetary missions 
against cancer, genetic diseases, neurological 
disorders, and radiation syndromes (TA 6.5.2.4, 
6.5.2.2, 6.5.2.1). However, the availability of 
these powerful therapeutics during missions is 
limited by their long-term stability under space-
flight conditions and the difficulty of 
determining the therapeutics one will need prior 
to take-off. On-demand protein therapeutic 
production will eliminate the need to store 
protein therapeutics long-term while also 
improving the versatility of in-flight biomedical 
countermeasures and treatments 
Cell-free Protein Synthesis 
The production of proteins requires biological 
processes as conducted by specialized cell 
machinery. The traditional method of protein 
manufacturing produces proteins within living 
cell cultures, or in vivo. Cell-based production 
platforms are dependent on the growth and 
replication of living cells and therefore require 
time intensive production, purification and 
protein isolation steps. Protein therapeutics are 
conventionally purffied and stored in aqueous or 
dried form in low temperature storage until 
administration. However, stability of these 
isolated proteins are limited over time and 
elevated temperatures. Cell-free systems are an 
emerging production platform that provides an 
alternative to the complicated manufacturing 
process. Protein therapeutic stability limitations 
can also be overcome by eliminating the need to 
store proteins on board spacecraft and instead 
produce them on-demand through CFPS.  
On-demand protein synthesis can enable crews to 
produce protein therapeutics as the need arises. 
Protein therapeutics are most commonly 
expressed in vivo; however, cellular systems are 
not particularly effective in the space 
environment due to cell destruction under 
ionizing radiation [4]. These in vivo systems also 
require a significant amount of equipment and 
complex purification steps. An alternative 
approach is through in vitro cell-free expression. 
CFPS systems make it possible to synthesize 
proteins outside of a cell by combining the DNA 
of the protein of interest with emancipated 
cellular machinery in a reaction vessel (Figure 3). 
Cell-free expression has been demonstrated on a 
wide array of therapeutic proteins including 
antibodies, vaccines, and cancer drugs [5]. CFPS 
technology facilitates rapid product purification 
with minimal equipment and provides an 
efficient protein production platform with high 
protein yields in as little as an hour which is an 
Figure 1: Illustration of CFPS: E. Coli cells are lysed for components to be used in CFPS system for the 
production of protein therapeutics or other biocatalysts. 
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order of magnitude faster than in vivo production 
[6]. 
Many cell types have been utilized for CFPS 
reactions; however, this project will use CFPS  
reagents harvested from the bacteria E. coli [5]. 
E. coli lysates are desirable for this work due to 
the robustness of E. coli machinery to harsh 
conditions and their rapid high-yielding 
capability [7, 8]. Currently, E. coli is the most 
cost-effect method to produce many complex 
proteins including insulin and antibodies [9]. 
While E. coli-based machinery may lack some 
machinery needed for post-translational 
modifications required by certain proteins, 
current work in the field is engineering this 
ability into the E. coli-based system [10].  
Regardless, optimizing E. coli-based CFPS will 
provide important reference data applicable to 
other cell-free systems.   
Lyophilization  
CFPS provides rapid recombinant protein 
production; however, the major components of a 
cell free system must be stored in aqueous 
solutions below freezing [9]. To ensure protein 
synthesis viability, the CFPS solutions are most 
commonly maintained at -80°C, requiring low 
temperature freezers. To overcome this 
drawback, lyophilization can be used to preserve 
CFPS systems. Lyophilization, or freeze-drying, 
is a commonly used preservation technique. We 
can utilize this technique on our CFPS systems 
because they do not require living cells. A CFPS 
system can therefore be created from lyophilized, 
shelf-stable reagents (Figure 4) [11]. These 
ready-made powdered CFPS systems are capable 
of high-density, thermostable storage with the 
proven capacity to produce protein therapeutics 
[12]. An example of a stored, small-scale 
lyophilized CFPS system is shown in Figure 2.  
Initial lyophilization work using freeze-dried cell 
extracts and separate powdered energy systems 
demonstrated that the lyophilized systems retain 
viability over a 60-day period at room 
temperatures [11] and in follow on work has 
demonstrated retained activity after 1 year when 
stored at 4°C. In comparison, all activity was lost 
in the non-lyophilized sample [12].  
Cryoprotectant additives can be considered for 
even greater retention of CFPS activity over 
longer storage periods. Initial studies using 
cryoprotectant have shown promise for 
prolonged storage [13].   
 
Figure 2: Image of Lyophilized CFPS system stored in 
test tube 6 months at room temperature 
As mentioned, previous iterations of lyophilized 
CFPS have required the cell extract and energy 
mix to be stored separately. One reason for this 
may be the hydrophobic nature of some of the 
components of the energy mix which may 
decrease dry storage. Separate storage of the cell 
extract and energy mix limits the convenience of 
the current lyophilized CFPS stems. A one-pot 
CFPS platform which only requires rehydration 
of water and addition of DNA template would 
provide a straightforward, user-friendly 
platform. To this aim this project sought to 
optimize cryoprotectant additives to enhance 
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preservation, especially with the addition of 
hydrophobic energy mix.  
Convenient Downstream Purification  
One of the most significant challenges to on-site, 
point-of-care production is purification 
efficiency and the risk of endotoxin exposure 
from incomplete purification of bacteria residue.  
Our lab recently developed an “endotoxin-free” 
CFPS system using an LPS-free cell strain as 
recently detailed [9]. By eliminating the source 
of toxic LPS, we have essentially eliminated this 
risk of endotoxin exposure due to therapeutic 
administration. 
Experimental Methods 
Data were collected on the effects of 
lyophilization methods on CFPS cell extract 
storage. Samples were were frozen in a -40°C 
ethanol bath (Just-A-Tilt Shell Freezer Chiller 
SF-4Az, FTS Systems, Warminster, PA). 
samples were then freeze dried (Flexidry MP, 
FTS Systems (Figure 3). After approximately 1.5 
hours of freeze-drying, samples reached 
minimum weight suggesting samples were 
sufficiently dried. 
Lyophilized CFPS systems were stored at 
elevated temperatures and tested periodically for 
protein synthesis activity. Activity was 
determined by measuring production levels of 
the fluorescent sfGFP protein.  To demonstrate 
the capacity of this system to produce protein 











Figure 4: Protein ribbon diagram representative of an 
FDA approved protein therapeutic [14]. 
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Results 
This project constitutes the an important 
advancement of lyophilized CFPS system 
capable of producing yields appropriate for 
therapeutic doses.  We have achieved an 
improved lyophilized CFPS system from those 
previously reported by our lab and others. This 
new system only requires rehydration with water 
and supplied with the DNA template of choice 
for on-demand CFPS protein production. This 
system was demonstrated to hold activity after 
storage at elevated temperatures. Therapeutic 
protein production was demonstrated. 
A full disclosure of the results of this project are 
document in an article which is being prepared 
for submission to a peer-reviewed journal.  The 
title of this article is “Thermostable 
Lyoprotectant-Enhanced Cell-free Protein 
Synthesis for On-demand Endotoxin-free 
Therapeutic Production” and it is anticipated that 
it will be published later in 2019.  
Conclusion  
Lyophilization, of cell-free systems creates rapid 
protein synthesis systems that can be created in 
mass and stored for later use. This ready-made 
powdered CFPS provides high density and non-
standard temperature storage improving the 
overall cost, transportability, and convenience of 
a CFPS system 
This work constitutes an important study for the 
design of lyophilized CFPS systems for 
prolonged storage by demonstrating the robust 
nature and therapeutic production capacity of a 
on-demand protein production platform. 
Significant progress has been made towards the 
development of practical on-demand CFPS 
systems for therapeutic protein production during 
long-term space flight.  
Future Work 
While a lyophilized, on-demand CFPS system 
has potential to provide life-saving protein 
therapeutics to space flight crews, the viability of 
this system under high-ionizing radiation 
exposure is unknown. Although the effects of 
radiation on DNA and in vivo biological 
processes have been extensively studied [4, 15, 
16], little has been done to understand the impact 
on the individual biological molecules that make 
up the basic machinery of life. A follow-on 
project will constitute the first study of the effects 
of radiation on CFPS system machinery in 
combined and isolated format.  
Despite the lack of research on radiation effects 
on this system, we expect to see decreased 
system activity due to the known degradation of 
macromolecular biological complexes by high-
level radiation [15, 16]. To overcome this 
potential challenge, we will utilize protective 
additives. Antioxidants have been shown to 
protect biological systems from radiation 
induced oxidation events and NASA has reported 
polyethylene as a shield to high-ionizing 
radiation [17]. Both are commonly added to 
CFPS systems and do not inhibit its protein 
production activity [18]. A lyophilized system 
with improved radiation resistance will be 
capable of providing on-demand therapeutics and 
reduce the need to store protein therapeutics 
long-term while also improving the versatility of 
in-flight medical treatments. 
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